TRST.TO - CannTrust Holdings Inc.

Toronto - Toronto Delayed Price. Currency in CAD
2.1400
+0.0200 (+0.94%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.1200
Open2.1500
Bid2.1200 x 0
Ask2.1400 x 0
Day's Range2.1000 - 2.1700
52 Week Range2.1000 - 15.5000
Volume927,815
Avg. Volume2,428,306
Market Cap302.134M
Beta (3Y Monthly)4.62
PE Ratio (TTM)N/A
EPS (TTM)-0.1210
Earnings DateMay 14, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.32
  • CNW Group

    S&P Dow Jones Indices Announces Changes to the S&P/TSX Composite Index

    S&P Dow Jones Indices Announces Changes to the S&P/TSX Composite Index

  • Here’s Why You Can’t Trust CannTrust Stock
    InvestorPlace

    Here’s Why You Can’t Trust CannTrust Stock

    If you've followed my work over the past year, you know that I'm a strong supporter of marijuana stocks. While the viability of individual names varies, overall, the lack of a defined upside excites me. In other words, the cannabis market could be the most transformative of our generation. Or it could crash and burn. For CannTrust Holdings (NYSE:CTST) and CannTrust stock, I'm referring to the latter.Source: Shutterstock In short, CTST stock could be the first of the major New York Stock Exchange-traded cannabis companies to implode. Granted, I'm not breaking new ground here. Since the beginning of July of this year, shares have cratered over 68%. It's a good thing that Stockcharts.com defaults to a logarithmic scale for their charts; otherwise, it'd be hard to fit that magnitude of a drop in nominal unit-based scale.Initially, the troubles for CannTrust stock began when Health Canada, the namesake country's federal health agency, discovered a shocking scandal: CannTrust was illegally growing cannabis. But it wasn't just the infraction against clearly defined rules and protocol that hemorrhaged CTST stock. Instead, it was the violation's deliberate nature.InvestorPlace - Stock Market News, Stock Advice & Trading TipsCannTrust employees, with the knowledge of executive leadership, created illegal grow rooms hidden behind false walls. Clearly, management premeditated their actions. Thus, it was no surprise that the company fired former CEO Peter Aceto with cause. * 10 Battered Tech Stocks to Buy Now If that wasn't bad enough for CannTrust stock, we have another scandal: black market cannabis seeds allegedly got mixed into CannTrust's inventory.While it's not as dramatic of a headline as the hidden grow rooms, this latest controversy could spell big trouble for CTST stock. Thus, I wouldn't even gamble on the name. CannTrust Stock Has Zero CredibilitySince its inception, virtually all marijuana companies sought one attribute: credibility.During the early stages of the green market, companies attempted to convince investors, potential partners and financial institutions that their underlying business was realistically viable. Right now, these same firms are attempting to show that they can convert some of these storylines into actual results.However, it's been a trying time. Established leaders, such as Cronos Group (NASDAQ:CRON), Canopy Growth (NYSE:CGC), Tilray (NASDAQ:TLRY) and most recently Aurora Cannabis (NYSE:ACB) have attempted to do this conversion through their earnings results. So far, they've failed spectacularly.But with CTST stock, you have the worst of both worlds. Obviously, if CannTrust knowingly created illegal grow rooms, investors can't trust their financials. And if the story about black-market seeds is true, the company can't even manage its own products. Thus, CTST has neither financial nor fundamental credibility.And that really means only one thing: CannTrust stock is a goner.Believe me: although the black-market seeds sound like a granular and perhaps inconsequential violation, it's actually an earth-shattering one.That's because we have a vaping crisis on our hands. Recently, President Donald Trump declared his intentions to ban all flavored e-liquids used in vaporizers. Citing an epidemic in underage vaping, Trump didn't appear open to negotiations.Now, if you dig into this story deeper, you'll recognize that the Food and Drug Administration is leaning toward illegally acquired THC-laden cannabis as a prime suspect for the surge in lung illnesses.I mention this because of the power of public perception. Tacitly, the FDA appears to suggest that proper, retail vaping products are fine to use. But with CannTrust's latest scandal, it proves that you can't even trust established, legitimate organizations.It's truly an ugly situation for CannTrust stock. Wall Street Has Lost Patience with CTST StockAlthough the vaping crisis has taken center stage, my opinion is this: the controversy will boil over eventually, leading to some reasonable concessions on both sides. For instance, many e-liquid companies need to take responsibility and stop using marketing that allures children.Anti-smoking advocates succeeded in eliminating Joe Camel, the Camel cigarette's once-popular brand face. Understandably, the cartoonish character attracted children, which of course is a big no-no. Anti-vaping advocates can do the same for donut-flavored e-liquids, for instance.But when it comes to CannTrust, I think the bad taste they created is simply too much. Seemingly everything about this company is a lie. Worse yet, their actions impugn the (hopefully) reputable behaviors of their peers. Since marijuana stocks tend to rise and fall in sympathy with each other, CannTrust stock will victimize many names.When the markets settle down, they'll give a second chance to the established leaders in this space. But for CTST stock, I think Wall Street has lost its patience. One massive scandal is already enough. But having two in a highly controversial market? Why bother with CannTrust when literally every other cannabis-based opportunity is better?As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Battered Tech Stocks to Buy Now * 7 Strong-Buy Stocks Hedge Funds Are Buying Now * The 7 Best Penny Stocks to Buy The post Herea€™s Why You Cana€™t Trust CannTrust Stock appeared first on InvestorPlace.

  • PR Newswire

    CannTrust Provides Default Status Report

    VAUGHAN, ON, Sept. 12, 2019 /PRNewswire/ – CannTrust Holdings Inc. ("CannTrust" or the "Company", TSX: TRST, NYSE: CTST) today is providing a status update in accordance with its obligations under the alternative information guidelines set out in National Policy 12-203 – Management Cease Trade Orders ("NP 12-203"), which require the Company to provide bi-weekly updates until such time as the Company is current with its filing obligations under Canadian securities laws. As previously announced, the Company is subject to a management cease trade order ("MCTO") issued by the Ontario Securities Commission.

  • CannTrust: Eight Capital Removed Its Target Price
    Market Realist

    CannTrust: Eight Capital Removed Its Target Price

    On Tuesday, Eight Capital removed its target price for CannTrust Holdings due to uncertainty about the risks involved in the company's future operations.

  • Are These Marijuana Stocks A Good Buy Now? Look Past The Hype
    Investor's Business Daily

    Are These Marijuana Stocks A Good Buy Now? Look Past The Hype

    Are marijuana stocks on U.S. exchanges a good buy now? The marijuana industry gets a lot of hype, but look past the smoke and analyze pot stocks on their fundamentals and technicals.

  • CannTrust Down Almost 65% in 2019—What’s Next?
    Market Realist

    CannTrust Down Almost 65% in 2019—What’s Next?

    On September 6, CannTrust Holdings (TRST) (CTST) was trading at 2.33 Canadian dollars. This marked a discount of 85% from its 52-week high.

  • Friday the 13th Won’t Be All Bad for Canada Stocks Rejig
    Bloomberg

    Friday the 13th Won’t Be All Bad for Canada Stocks Rejig

    (Bloomberg) -- Air Canada fell as much as 1.5% on Monday after the stock was unexpectedly left out of a reshuffle of the S&P/TSX 60 Index and Kirkland Lake Gold Inc. added instead.Kirkland Lake rose 2.8% at 9:50 a.m. in Toronto after the announcement late Friday; Husky Energy Inc. was removed in the changes. S&P Dow Jones is still set to announce the changes for the TSX composite on Sept. 13.READ MORE: A Hidden Gem May Join The Big Leagues After Canada Index ShuffleThe index changes -- important in the age of passive investing since they drive the composition of exchange traded funds -- may turn out to be the biggest news in what’s expected to be a relatively quiet week. Expect CannTrust Holdings Inc. to be among those ejected from the composite index after it fell beneath its listing price of C$2.50.Kirkland Lake has soared 80% this year amid gold’s safe-haven rally and is up 675% over three years.Air Canada had climbed more than 300% since 2016 and is the best-performing stock in the Bloomberg World Airlines Index this year. The carrier’s performance has been boosted this year by its planned acquisition of tour operator Transat AT, which will accelerate its global presence in the leisure industry.CannTrust, on the flipside, has fallen almost 85% from its 2018 peak. A demotion from the TSX would mean it has spent a mere six months in the index.To be eligible for index inclusion, a stock must have a float-adjusted market cap of greater than 0.04% of the index itself, according to AltaCorp. It should also have a float turnover of more than 0.5 times over the period of the prior year. For a deletion, the stock will have a float weight of less than 0.025% of the index. The measurement period to determine changes is based on volume-weighted trading over the last 10 trading days of August.The conference schmoozefest will continue with Canadian companies presenting across North America: Barclays Global Financial Services Conference, Rodman & Renshaw 21st Annual Global Investment Conference, RBC Global Industrials Conference and BMO Media & Telecom Conference.Here’s a recap of what happened last week:Markets -- Just The NumbersWhile skepticism remains, markets were buoyed by the easing of U.S.-China trade tensions this week. A spate of good economic data up north supported the Bank of Canada’s reluctance to signal a potential interest rate cut when it held interest rates steady. That culminated with a blockbuster 81,100 jobs created last month, Statistics Canada reported Friday. It was the seventh-largest monthly gain in records going back to 1976, and brought gains to 471,300 over the past 12 months, the most in a year since 2003.Chart of The WeekPoliticsPrime Minister Justin Trudeau is expected to kick off Canada’s election campaign over the next week. The federal election is set to take place on Oct. 21.EconomyEconomists will have one eye on August housing starts, expected on Sept. 10, after the Bank of Canada kept rates unchanged in September, in contrast to the rest of the world’s easing trend. Deputy Governor Lawrence Schembri on Thursday noted the domestic economy’s resilience, highlighting the bank’s determination to chart its own course.TrendingInCanada1\. Tennis superstar (and Canadian!) Bianca Andreescu made history and won the US Open in New York last week. And in true Canadian fashion, she apologized to fans of Serena Williams for her win.(Updates with S&P/TSX 60 shuffle announcements, share price)\--With assistance from Madeleine Lim.To contact the reporters on this story: Divya Balji in Toronto at dbalji1@bloomberg.net;Aoyon Ashraf in Toronto at aashraf7@bloomberg.netTo contact the editors responsible for this story: Madeleine Lim at mlim131@bloomberg.net, Jacqueline Thorpe, David ScanlanFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Benzinga

    Cannabis Countdown: Top 10 Marijuana Industry News Stories Of The Week

    Cannabis Countdown: Top 10 Marijuana Industry News Stories of the Week Welcome to the  Cannabis Countdown . In this week’s rendition, we’ll recap and countdown the top 10  marijuana industry news  stories ...

  • Even Though Aurora Cannabis Has a Future, Lay off ACB Stock for Now
    InvestorPlace

    Even Though Aurora Cannabis Has a Future, Lay off ACB Stock for Now

    Aurora Cannabis (NYSE:ACB) is not having a good year. After shooting up nearly 80% in the first two-and-a-half months of 2019, the ACB stock price has fallen dramatically.Source: ElRoi / Shutterstock.com Even encouraging preliminary fiscal fourth-quarter revenue was not enough to prevent the stock from continuing to decline. Aurora Cannabis stock is currently hovering at a gain of about 10% for the year. However, some analysts suggest it still has room to fall.But are the problems that plague Aurora Cannabis stock unique to ACB? Are they part of a larger industry problem? Or are they completely unrelated? The answer may be a little of each, but in my opinion, it comes down to this: Aurora is having problems shouldering the weight of unrealized, and perhaps unrealistic, investor expectations.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cannabis Stocks Are Down Across the BoardThis year hasn't quite worked out the way the large Canadian cannabis producers, had imagined. Regulatory approval through Health Canada has taken longer than expected. This caused the market to be oversupplied. This is not good news for Aurora who, along with Canopy Growth (NYSE:CGC) is one of the largest producers in Canada. * 7 Deeply Discounted Energy Stocks to Buy Then, in July, news broke about CannTrust (NYSE:CTST) growing marijuana in unlicensed rooms. This was not an Aurora problem. However, the message to spooked investors was clear. The still emerging cannabis market continues to have a risk premium.Yet it's apparent that neither of these was caused by Aurora. The company didn't make promises that they couldn't deliver on. But this is what happens when a bubble bursts. When investors can't punish themselves, they punish the innocent as well as the guilty. Fundamentals Are Taking Control of the FrenzyAs the cannabis bubble began to inflate, Aurora did what many leaders in emerging markets would do, they issued more shares. This was a reasonable course of action, particularly as the cannabis market entered the growth-through-acquisition state. But as the number of outstanding shares went through the roof, analysts started to balk at the serious dilution that was happening with ACB stock.Analysts also sounded the alarm about Aurora Cannabis stock being used to finance the company's current and future acquisitions. In 2018, Aurora Cannabis completed the acquisitions of CanniMed Therapeutics and MedReleaf. More acquisitions spell higher volatility and further stock dilution. All of which means investors may be waiting a while to see a return on their investment.But again I say this is what happens in a bubble. All of the major Canadian cannabis stocks, including Aurora, have balance sheet issues. Many have a large price-to-sales ratio (around five times higher than other industries). And all of the big cannabis companies are executing some form of the growth-through-acquisition model. Regulation and Legalization Are Still ObstaclesWhat makes the cannabis story so intriguing is that both the supply and the demand exist. The problem is access. The major obstacles for Aurora come in the form of regulation (in Canada) and legalization (in the United States).Canada voted on full legalization of marijuana (medicinal and recreational) in 2018. This gave investors hope that 2019 would be the year that Canadian companies, such as Aurora, would post earnings that reflected full quarters with legalized sales.Through no fault of Aurora that hasn't materialized. Because of regulatory delays, the market in Canada will not be fully open until December. This means investors and analysts won't be able to assess ACB stock using conventional valuation metrics like EBITDA until after the 2020 first-quarter earnings.And while Aurora and other companies wait for regulatory approval in their home country, they are increasingly looking to the United States market. But here they're finding the market stalled as the U.S. still wrestles with the idea of full legalization. While I still believe that full legalization will happen sooner rather than later a small, vocal minority (mostly the "not in my backyard" crowd) may make progress towards this goal slower than investors would like. What's Next for Aurora Cannabis Stock?Cult stocks like Tesla (NASDAQ:TSLA) seem to be able to get away with failing to deliver on spurious projections. However, investors seem to hold Aurora to a higher standard. But it is sounding more and more like investors are punishing ACB stock for not being able to save them from themselves.Anyone investing in Aurora has to understand that it is a growing company in an emerging and volatile market. I wouldn't buy ACB right now. It seems like no matter what happens when it reports its earnings later this month that it has further to fall.But I'm still bullish on the long-term potential for Aurora Cannabis stock, particularly once investor expectations start matching up with the reality, and potential, of the stock.As of this writing, Chris Markoch did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 3 Artificial Intelligence Stocks to Buy * 7 Industrial Stocks to Buy for a Strong U.S. Economy * 3 Beaten-Down Bank Stocks to Buy and Hold for the Long Term The post Even Though Aurora Cannabis Has a Future, Lay off ACB Stock for Now appeared first on InvestorPlace.

  • Marijuana Stocks Mostly Rise Despite Latest Illicit Supply Report
    Investor's Business Daily

    Marijuana Stocks Mostly Rise Despite Latest Illicit Supply Report

    Citing internal documents, BNN Bloomberg said CannTrust grew more than 1,000 plants from seeds that came from the illicit market

  • Cannabis Roundup: CTST, CRON, OGI, ACB, and WEED
    Market Realist

    Cannabis Roundup: CTST, CRON, OGI, ACB, and WEED

    Cannabis ETFs the ETFMG Alternative Harvest ETF and the Horizons Marijuana Life Sciences Index ETF were up 2.0% and 1.7%, respectively, at 1:20 PM today.

  • 3 Pot Stocks to Avoid Like the Plague in September
    Motley Fool

    3 Pot Stocks to Avoid Like the Plague in September

    These marijuana stocks are unlikely to have investors seeing green in the near term.

  • Here’s How Millennials Can Save Hexo Stock … and Maybe its Cannabis Peers
    InvestorPlace

    Here’s How Millennials Can Save Hexo Stock … and Maybe its Cannabis Peers

    It's becoming a sad, familiar scene in the broader marijuana industry. Like so many other sector players, Hexo (NYSE:HEXO) started out this year on fire. But as we flipped the pages of the calendar, investors started to see less appeal for botanical goods. As a result, the Hexo stock price has charted a severely bearish trend channel since late April.Source: Shutterstock In my opinion, some of the negativity is unwarranted. Whether we like it or not, cannabis stocks tend to move in sympathy with each other. That's great when we have collectively bullish news, such as Canada legalizing recreational weed. But negative events, such as the CannTrust (NYSE:CTST) controversy, have hurt the Hexo stock price.In early July, Canadian health officials discovered that CannTrust illegally grew cannabis in unlicensed rooms. That set off a wildfire within the industry, which so far culminated in CannTrust firing its CEO. While this incident has nothing to do with HEXO, cannabis companies eagerly seek legitimacy and credibility.InvestorPlace - Stock Market News, Stock Advice & Trading TipsUnfortunately, this incident was incredibly unhelpful for Hexo stock. Since the incident came to light, the company's equity has plunged roughly 16%.That said, let's face facts: Hexo stock has enough of its own problems on paper to justify its volatility. For instance, while its fiscal third-quarter earnings results weren't terrible, they failed to meet analysts' expectations for per-share profitability. And this is where the honeymoon phase has dried up for HEXO: Wall Street wants substantive results, and they're not getting it. * The 8 Worst Stocks to Buy Before the Trade Turmoil Cools Off Naturally, many folks are saying to hold off on buying Hexo stock until this situation improves. Hexo Stock Primed to Advantage Key Demographic RealityPersonally, I'm speculating on HEXO, so I'm biased. Nevertheless, I can see the wisdom in a patient approach. For example, my InvestorPlace colleague Todd Shriber recommended waiting out shares until they stabilize.This is very sound advice. If we were talking about blue chips, I would say the same thing ad nauseum. However, we're talking about the cannabis industry. It's unlike any other sector because we don't know legal marijuana's ceiling.If we see federal legalization of weed in the U.S., it can skyrocket the Hexo stock price, along with peers like Aurora Cannabis (NYSE:ACB) and Cronos Group (NASDAQ:CRON). But if Canadian legalization is the industry's peak, well, I would have made one of my dumbest moves yet.Logically, most cannabis companies are banking on the U.S. legalization potential. Politically, I believe momentum favors the optimists. Thus, I'm not overly concerned about HEXO's expansionary efforts because I believe their efforts will be rewarded in the long run.But along the lines of marijuana being an unprecedented market, we must also appreciate their target consumer base: millennials. While most of the country supports marijuana legalization, millennials overwhelmingly (74%) support the cause.More importantly for the Hexo stock price, evidence indicates that millennials are narrative-driven investors. CNBC calls it emotional investing. But the bottom line is that young people are guided by purpose and principles. Therefore, their investments are more likely to reflect their lifestyle or personal ethos.And that truly augurs well for HEXO. I'll concede again that on paper and against traditional financial metrics, the company doesn't look too hot. But really, who cares? I don't mean to sound flippant, but their target audience is youthful investors, not stodgy, "by the book" baby boomers. Look at HEXO Through a Young Person's LensLately, bearish stories about legal marijuana have a recurring theme: don't jump aboard because the industry is unproven and unstable. They may throw in specific details about the financial statements, such as negative income trends. * 7 Best Tech Stocks to Buy Right Now All of these things and more are true for Hexo stock. But again, bear in mind that the underlying company's target audience is young people. They're least likely to care as much about the financials. Instead, they're looking for a convincing narrative.HEXO has that in spades. Moreover, shares have a cheap ticket price. That's also important for younger millennials, who are burdened with college debt and other life expenses.Don't get me wrong: Hexo stock is still an incredibly speculative and risky name. But its potential for an upswing isn't nearly as ludicrous as you might think.As of this writing, Josh Enomoto is long HEXO. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Deeply Discounted Energy Stocks to Buy * 7 Stocks to Buy In a Flat Market * 10 Stocks to Buy to Ride China's Emerging Wealth The post Here's How Millennials Can Save Hexo Stock a€¦ and Maybe its Cannabis Peers appeared first on InvestorPlace.

  • Why Cronos Group Stock Stands Out in a Sea of Cannabis Sameness
    InvestorPlace

    Why Cronos Group Stock Stands Out in a Sea of Cannabis Sameness

    Cronos Group (NASDAQ:CRON) in late July announced the purchase of four subsidiaries of Redwood Holding Group. Like other recent acquisitions, the Redwood buy demonstrates how Cronos is taking a distinctly different path to growth than its major competitors. This difference, though, is not reflected in CRON stock at the moment.Source: Shutterstock In its last earnings period, Cronos Group easily beat analysts' expectations for revenue, posting $10.24 million (vs. expectation of $7.36 million). This was after a first quarter in which it posted a 120% YoY revenue increase.Despite these positive revenue numbers, CRON stock is down 50% since February. Some of this is an overreaction to the behavior of CannTrust Holdings (NYSE:CTST). In July, CannTrust was found guilty of growing marijuana in unlicensed rooms. The fallout affected the entire industry, which was already falling from its 2018 highs.InvestorPlace - Stock Market News, Stock Advice & Trading TipsStill, prior to July, CRON stock was down 11.7% while the ETFMG Alternative Harvest ETF (NYSEArca:MJ), lost 4.66%. Cronos Group stock is the second-largest holding in the 38-stock cannabis exchange-traded fund.Questions abound about the companies short- and long-term profitability. Their PS ratio of 191 doesn't help matters.At a quick glance, Cronos may look similar to many established cannabis companies. But as I mentioned above, CRON is taking a different path to growth. My InvestorPlace colleague Will Healy points out that Cronos is under the tutelage of their major investor and tobacco giant, Altria (NYSE:MO). And that path gives me two reasons to be optimistic about their future growth. An Asset-Light Approach to GrowthMany of the major cannabis companies are making acquisitions to help their cultivation efforts. Cronos is adopting a supply chain that focuses on a network of co-manufacturing joint ventures and partners. Redwood is the latest example. This was the company's first effort to enter the U.S. marijuana market. The acquisition is consistent with CRON's attempts to position itself to fit the growing demand for CBD-based beauty products. * 7 Best Tech Stocks to Buy Right Now Another example of Cronos Group's innovative approach took place in 2018. At that time, the company entered into a partnership with Gingko Bioworks. This is a bioengineering company that produces cannabinoids through biosynthesis. This partnership is helping CRON reduce the cost of cannabis production and positions them to produce minor cannabinoids such as tetrahydrocannbivarin (THCV) on a large scale. THCV has a number of health benefits, such as its ability to suppress appetite, that are not present in other forms of cannabinoids (i.e., THC or CBD). CRON is also aggressively carving out a niche in the Canadian derivatives market. This includes products like vaping pens, edibles, and topicals. CRON has agreement in place with third-party suppliers who will use Cronos' proprietary formulations in their products. Although other companies have a larger addressable market at the moment, these agreements will give Cronos Group a seat at the table. Cronos is Doing Right by its ShareholdersMost cannabis companies are financing their acquisitions with a secondary stock offering. This nifty accounting trick is common with real estate investment trusts (REITs). However, since a REIT is obligated to pay out a dividend, shareholder value is not diluted.But the major cannabis companies are not issuing dividends. This means that with every secondary offering they are diluting the value of their shares. Investors are catching on and it is showing up in the stock price for these companies.Here again, Cronos is doing things differently. They are paying for most of the Redwood acquisition in cash. Specifically, the cash they received from Altria, that made a major investment in Cronos Group in 2018. * The 8 Worst Stocks to Buy Before the Trade Turmoil Cools Off According to reports, the company will pay $225 million of the $300 million in cash. The rest will be paid by issuing common shares (valued at $14.74). Even after the purchase, CRON will still be sitting on nearly $1.5 billion in cash. Putting that cash to work is what shareholders expect. Plus, paying in cash means that Cronos is effectively managing its debt load. Cronos' long-term debt is about $15 million which is pocket change compared to the $700 million that is owed by Canopy Growth (NYSE:CGC).This is a compelling story that many investors aren't hearing about yet. And it's why Cronos stock may be one of the best deals going, not only in the cannabis sector but in the broader market as well. What's Next for CRON Stock?I foresee investors will look to re-enter the cannabis sector as the derivatives market opens in Canada in December. When they do, I believe CRON stock will stand out. One of the major reasons for my conviction is that the company is showing its value to investors. Put simply, when Cronos sees its market cap rise, it will be due to repeatable revenue and share price appreciation, not because of an accounting trick.As of this writing, Chris Markoch did not hold a position in any of the aforementioned stocks. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Deeply Discounted Energy Stocks to Buy * 7 Stocks to Buy In a Flat Market * 10 Stocks to Buy to Ride China's Emerging Wealth The post Why Cronos Group Stock Stands Out in a Sea of Cannabis Sameness appeared first on InvestorPlace.

  • Reuters

    CannTrust Holdings reduces workforce by 180 people

    The majority of the employees affected by the layoffs were in cultivation and customer service support roles, the Canadian marijuana producer said. "We have made the extremely difficult decision to restructure our workforce to reflect the current requirements of our business," CannTrust's interim Chief Executive Officer Robert Marcovitch said in a statement.

  • PR Newswire

    CannTrust affirms its commitment to regulatory compliance and restoring trust

    VAUGHAN, ON, Sept. 5, 2019 /PRNewswire/ - CannTrust Holdings Inc. ("CannTrust" or the "Company") (TSX: TRST, NYSE: CTST) announced today that both the Special Committee of its Board and its new executive leadership team continue to make progress on bringing CannTrust's operations and procedures into full regulatory compliance and ensuring the Company's future. As part of these efforts, the Company is reducing its workforce.

  • Cannabis Roundup: WEED, ACB, ACRGF, and CTST
    Market Realist

    Cannabis Roundup: WEED, ACB, ACRGF, and CTST

    News that the US and China plan to revive trade talks in October boosted the US stock market. Most of the cannabis players traded in the green today.

  • Newsfile

    CANNTRUST INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In CannTrust Holdings Inc. To Contact The Firm

    New York, New York--(Newsfile Corp. - September 4, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against CannTrust Holdings Inc. (NYSE: CTST) ("CannTrust" or the "Company"). If you invested in CannTrust stock or options and would like to discuss your legal rights, click here: www.faruqilaw.com/CTST. There is no cost or obligation to you.You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or ...

  • HEXO: What’s the Word on the Street?
    Market Realist

    HEXO: What’s the Word on the Street?

    HEXO stock has suffered since it reported lower-than-expected third-quarter results in June. The stock has fallen 31.8% since its earnings on June 12.

  • Benzinga

    The 5 Biggest Cannabis Business Scandals: From CannTrust To PotNetworks

    All are terrible and the size of those schemes may make the cannabis industry scandals look like small potatoes. Sadly the stereotype exists in part because it happens in the wild west days of cannabis penny stocks. This past July, PotNetworks (OTC: POTN) President Charles Vaccaro made contact with an undercover FBI agent saying “He was looking for someone to help them liquidate around $100 million in stock in multiple companies and it had to be processed in a foreign brokerage account because the Securities and Exchange Commission was getting tougher on U.S. broker-dealers liquidating large blocks of penny stock.” He and two others, Eli Taieb and Dror Svorai, were all charged with securities fraud, wire fraud, and conspiracy.

  • Benzinga

    Cannabis Execs: Uptick In Enforcement Does Not Signal Increase In Violations

    Curaleaf Holdings Inc (OTC: CURLF) found itself having to respond to a Food and Drug Administration's letter regarding CBD product marketing. Harvest Health & Recreation Inc (OTC: HRVSF) had its licenses suspended by the state of Ohio in July 2019 after a series of allegations that included taking advantage of licensing opportunities for economically disadvantaged groups. In Canada, CannTrust Holdings Inc (TSE: TRST) has had two of its facilities deemed non-compliant by Health Canada.